Australian scientists are working to improve medical devices for lung cancer treatment, sharing the outcome of their recent study in ‘Incorporating Chemotherapeutic Drug into a Personalizable Silicone Airway Stent for the Treatment of Lung Cancer and Tracheobronchomalacia.’
With a focus on relieving serious symptoms like central airway obstruction (CAO), the research team experimented with 3D printing molds to produce drug-eluting personalized airway stents, incorporated with chemotherapy drugs like Paclitaxel that inhibit the growth of cancer cells.Because diseases like lung cancer may leave patients struggling to breathe, pharmaceutical treatments and the use of effective devices can be critical to the quality of their lives—and even saving them in some cases. The researchers note that there are challenges with airway stents being used today due to a lack of personalization for patients, resulting in airway stent therapy that is often not effective. There may be other issues too, such as stent migration cased by improper fit.
“Unfortunately, airway stents have not developed, in large due to low relative prevalence of surgery and poor outcomes, since the release of Montgomery and Dumon stents during 1965 and 1989 respectively, despite leaps in 3D imaging and drug release technologies,” explain the researchers.
Drug-eluting stents offer potential in eliminating toxicity in delivery, as well as offering much-needed customizations for patients for better fit—reaping the rewards of one of the greatest benefits of 3D printing for the medical arena today with patient-specific treatment rather than a ‘one-size-fits-all’ premise for everyone. These benefits are heavily evidenced today in areas like prosthetics, heart valves, bio-active patches, and more.
Paclitaxel was added to the silicone molds, leaving the team of researchers to then perform a detailed assay on the Beas-2B cells derived from healthy patients and H23 adenocarcinoma cells derived from nonsmall cell lung cancer patients. The drug was insoluble in PBS, while ‘highly soluble in ethanol.’
Variances in release rates of drugs demonstrate the potential for further manipulation, with adjustments to the paclitaxel in silicone coupons or via other techniques. The authors reported that there has been similar success with other stents.
“The implications of characterizing a successful controlled release of paclitaxel from cured liquid silicone rubber will allow clinicians to personalize treatment depending on airway geometry and control for the targeted dose of paclitaxel to the area of interest, thereby reducing the side effect profile of paclitaxel and its excipients (i.e. ethanol and polyoxyethylated castor oil) in systemic circulation,” stated the researchers.
“Further assessment in the comparability of paclitaxel release into lung-like environment is needed to characterize the effectiveness of drug release.”
What do you think of this news? Let us know your thoughts; join the discussion of this and other 3D printing topics at 3DPrintBoard.com.[Source / Images: ‘Incorporating Chemotherapeutic Drug into a Personalizable Silicone Airway Stent for the Treatment of Lung Cancer and Tracheobronchomalacia’]
You May Also Like
Trump the Mundane Performance in Smart Printing — Creality CR-10 Smart Vanquishes with Advanced Functions
In an era that 3D printing functions seems to sit in a stereotyped mundane track, how to renovate turns to be of much importance that often draws the attention of...
The Boat Builder, the EinScan H and Fusion 360: Craftsmanship Meets Technology
From the heart of the UK to the sea The Cotswolds, a region located in the heart of the UK is not where one might expect to find a boat...
3D Printing Webinar and Event Roundup: July 10th, 2021
We’ve got another busy week of industry webinars and events, both virtual and in-person, to tell you about! Topics range from automotive 3D printing and 3D printing steel to point-of-care...
Parkway VC Launches $60M Fund Targeting Simulation and AI Startups
Emerging New York investment firm Parkway Venture Capital is raising up to $60 million for its second fund aimed at startups pioneering artificial intelligence (AI) and simulation developments to drive...
View our broad assortment of in house and third party products.